Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Shah I, Antony S, Jaiswal A, Bodhanwala M, Shah D, et al.
Introduction The prevalence of multidrug resistant (MDR) tuberculosis (TB) with additional resistance to fluoroquinolones or second-line injectables (MDRFQ/SLI)/extensively drug-resistant TB (XDR-TB) in children is high in Mumbai. There are limited therapeutic options available i…
Clemens DL, Lee BY, Silva A, Dillon BJ, Masleša-Galić S, et al.
…ile many TB drugs are available, identification of the best regimens is challenging because of the large number of possible drug-dose combinations. We have found consistently that responses of cells or whole animals to drug-dose stimulations fit a parabolic response surface (PRS)…
Nguyen TMP, Nguyen BH, Hoang TTT, Nguyen HA, Vu DH, et al.
…on (WHO) recently recommended standardized all-oral shorter regimens for rifampicin resistant Tuberculosis (RR-TB). For highly resistant Tuberculosis patients such as pre-XDR-TB: RR-TB plus additional resistance to fluoroquinolones (FQ), the 6-9-months bedaquiline (bedaquiline)-b…
Muniyandi M, Ramesh PM, Wells WA, Alavadi U, Sahu S, et al.
Objective To measure the economic impacts of the longer pre-XDR-TB treatment regimen and the shorter BEAT-TB India regimen. Methods In the current study, the economic impacts of the current 18-month pre-XDR-TB treatment regimen and the 6-9 month BEAT-TB regimen were evaluated usi…
Thi Mai Phuong Nguyen, Van Luong Dinh, Binh Hoa Nguyen, Thi Thanh Thuy Hoang, Viet Nhung Nguyen, et al.
…in-resistant TB (RR-TB) burden country. Different new RR-TB regimens were recommended in recent years. Locally-generated evidence about nationwide implementation of different RR-TB regimens is essential to inform national treatment guidelines. **METHODS:** A retrospective cohort…
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
… of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (B…
Animesh Sinha, Roland Klebe, Michael L Rekart, Jose Luis Alvarez, Alena Skrahina, et al.
…ll-oral bedaquiline, pretomanid, and linezolid (BPaL)-based regimens have demonstrated higher rates of treatment success and have been recommended by the World Health Organization. Operational research is urgently required to evaluate these regimens in non-trial settings. **METH…
Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, et al.
… medical patient costs were negligible across all treatment regimens, while direct non-medical patient and guardian costs for travel, food and nutritional supplementation accounted for the largest proportion of total costs ($54.6, $227.8 and $224.3 for BPaL, the SSOR and SLOR res…
Fu L, Zhang X, Xiong J, Sun F, Weng T, et al.
Objectives Long, ineffective, and toxic regimens hinder the treatment of patients with multidrug-resistant tuberculosis (MDR-TB) and pre-extensive drug-resistant tuberculosis (pre-XDR-TB). Methods We conducted a multicenter cohort study to prospectively evaluate the safety and ef…
Zhang SJ, Yang Y, Sun WW, Zhang ZS, Xiao HP, et al.
…ess and safety of bedaquiline (BDQ)-containing and BDQ-free regimens for treatment of patients with refractory RR/MDR/XDR-TB. Methods Patients with refractory RR/MDR/XDR-TB receiving BDQ-containing regimens (BDQ group, n = 102) and BDQ-free regimens (non-BDQ group, n = 100) satis…
Ivy Rukasha, Kabelo Gabriel Kaapu, Sarah M Fortune, Molebogeng Ruth Lekalakala-Mokaba
…ne (BDQ) has now become part of all standard drug-resistant regimens globally. However, emerging BDQ resistance is a growing worry, especially in areas with high rates of TB and HIV. This study aimed to compare BDQ-based regimens to non-BDQ-based treatments over a four-year perio…
Pirmahmadzoda B, Hann K, Akopyan K, Grigoryan R, Geliukh E, et al.
…, and Tajikistan did so in 2013 and 2017. Novel and adapted regimens included individual regimens for RR/MDR, XDR (with and without Bedaquiline and Delamanid) and short treatment regimens with and without injectables. It is important to document the outcomes of the treatment regi…
van de Berg SEJ, Pelzer PT, van der Land AJ, Abdrakhmanova E, Ozi AM, et al.
…ernative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, and success rates, and hence to limit patient burden, loss to follow-up and the emergence of resistance it is essential to implement new DR-TB regimens. …
Liu H, Zhu H, Fu L, Zhang W, Chen X, et al.
…ein synthesis inhibition, may undermine the efficacy of LZD regimens, and oxazolidinones with higher efficacy and lower toxicity during prolonged administration are needed. OTB-658 is an oxazolidinone anti-TB candidate derived from LZD that could replace LZD in TB treatment. We p…
Ignatius EH, Swindells S
…mong people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB…
Tanneau L, Karlsson MO, Svensson EM
…tion, and to explore the performances of alternative dosing regimens through simulations. Methods The bedaquiline exposure-response relationship was validated using time-to-positivity data from 233 newly diagnosed or treatment-experienced patients with drug-resistant tuberculosis…
Yang Li, Yilin Zhang, Lingyun Song, Cui Cai, Yuanyuan Chen, et al.
… treatment options and significant disease burden. Existing regimens have shown high success rates but are often inaccessible globally, necessitating alternative options. **METHODS:** This study was an open-label, multicenter, single-arm study conducted in China to evaluate the …
Riccardi N, Alagna R, Saderi L, Ferrarese M, Castellotti P, et al.
… to retrospectively compare MDR-TB and pre-XDR-TB treatment regimens and outcomes in two large TB reference centres in Italy from January 2000 to January 2015. Methods A retrospective, multicentre study was conducted at the Regional TB Reference Centre Villa Marelli Institute (Mi…
Jason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, Ashely Romano, Samantha Pauly, et al.
…acy of bedaquiline, delamanid, and linezolid (BDL) and BPaL regimens in a high-burden preclinicalmouse model. Treatment with pretomanid and delamanid monotherapies and dual therapy with bedaquiline-linezolid was also conducted for comparison. Mice were treated for 2, 4, or 8 week…
Mpobela Agnarson A, Williams A, Kambili C, Mattson G, Metz L
Background : Bedaquiline-containing regimens have demonstrated improved outcomes over injectable-containing regimens in the long-term treatment of multidrug-resistant tuberculosis (MDR-TB). Recently, the World Health Organization (WHO) recommended replacing injectables in the sta…
Wamaka Kaminyoge, Reuben Simfukwe, Mwiza Singini, Norman Sitali, Felix P Chilunga
…B) face major treatment challenges. Although newer all-oral regimens have transformed adult TB care, their use in younger populations has largely been extrapolated from adult studies, despite important biologic and clinical differences. Systematic and up-to-date evidence on the e…
Li S-Y, Tyagi S, Soni H, Betoudji F, Converse PJ, et al.
…stance necessitate efforts to develop new short-course oral regimens. We recently found that the addition of GSK2556286 increases the bactericidal and sterilizing activity of BPa-containing regimens in a well-established BALB/c mouse model of tuberculosis. Here, we used this mode…
Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, et al.
…omise for combination in shorter, less-toxic, and effective regimens. To date, there has been no randomized, internally and concurrently controlled trial of a shorter, all-oral regimen comprising these newer and repurposed drugs sufficiently powered to produce results for pre-XDR…
Yao Qin, Yuanyuan Chen, Qingshan Cai
…atment challenges, requiring effective and safe therapeutic regimens. This study aims to assess the efficacy and safety of a 24-week regimen that includes Delamanid (Dlm) for patients with these resistant forms of tuberculosis. **METHODS:** This was a single-arm, prospective, mo…
Li SY, Converse PJ, Betoudji F, Lee J, Mdluli K, et al.
…the clinically successful BPaL regimen may lead to superior regimens capable of treating both drug-susceptible and drug-resistant TB more effectively and safely.